Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4+ T‐cell‐independent CD8+ T‐cell‐mediated tumor control

Antigen‐specific immunotherapy is an attractive strategy for cancer control. In the context of antiviral vaccines, adenoviral vectors have emerged as a favorable means for immunization. Therefore, we chose a strategy combining use of these vectors with another successful approach, namely linkage of the vaccine antigen to invariant chain (Ii). To evaluate this strategy we used a mouse model, in which an immunodominant epitope (GP33) of the LCMV glycoprotein (GP) represents the tumor‐associated neoantigen. Prophylactic vaccination of C57BL/6 mice with a replication‐deficient human adenovirus 5 vector encoding GP linked to Ii (Ad‐Ii‐GP) resulted in complete protection against GP33‐expressing B16.F10 tumors. Therapeutic vaccination with Ad‐Ii‐GP delayed tumor growth by more than 2 wk compared with sham vaccination. Notably, therapeutic vaccination with the linked vaccine was significantly better than vaccination with adenovirus expressing GP alone (Ad‐GP), or GP and Ii unlinked (Ad‐GP+Ii). Ad‐Ii‐GP‐ induced tumor control depended on an improved generation of the tumor‐associated neoantigen‐specific CD8+ T‐cell response and was independent of CD4+ T cells. IFN‐γ was shown to be a key player during the tumor degradation. Finally, Ad‐Ii‐GP but not Ad‐GP vaccination can break the immunological non‐reactivity in GP transgenic mice indicating that our vaccine strategy will prove efficient also against endogenous tumor antigens.

[1]  Bjoern Peters,et al.  Lymphocytic Choriomeningitis Virus Infection Yields Overlapping CD4+ and CD8+ T-Cell Responses , 2008, Journal of Virology.

[2]  T. Mak,et al.  TNF-α is critical for antitumor but not antiviral T cell immunity in mice , 2007 .

[3]  D. von Laer,et al.  Decreased tumor surveillance after adoptive T-cell therapy. , 2007, Cancer research.

[4]  R. Fairchild,et al.  Regulatory function of CD4+CD25+ T cells from Class II MHC‐deficient mice in contact hypersensitivity responses , 2007, Journal of leukocyte biology.

[5]  J. Christensen,et al.  Rapid and sustained CD4(+) T-cell-independent immunity from adenovirus-encoded vaccine antigens. , 2007, The Journal of general virology.

[6]  Sebastian Amigorena,et al.  In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor , 2007, The Journal of experimental medicine.

[7]  M. Carroll,et al.  Recombinant viral vectors: cancer vaccines. , 2006, Advanced drug delivery reviews.

[8]  C. Blank,et al.  Immune resistance orchestrated by the tumor microenvironment , 2006, Immunological reviews.

[9]  R. Dutton,et al.  This information is current as Apoptosis of Cells of a Solid Tumor Expansion , Migration , and Leads to Regulates Donor CD 8 T Cell γ IFN - , 2006 .

[10]  T. Gajewski.  Identifying and Overcoming Immune Resistance Mechanisms in the Melanoma Tumor Microenvironment , 2006, Clinical Cancer Research.

[11]  H. Pircher,et al.  Solid tumors “melt” from the inside after successful CD8 T cell attack , 2006, European journal of immunology.

[12]  R. Dutton,et al.  The Rate of the CD8-Dependent Initial Reduction in Tumor Volume Is Not Limited by Contact-Dependent Perforin, Fas Ligand, or TNF-Mediated Cytolysis1 , 2004, The Journal of Immunology.

[13]  G. Maelandsmo,et al.  Helper-Dependent Adenovirus Vectors Elicit Intact Innate but Attenuated Adaptive Host Immune Responses In Vivo , 2004, Journal of Virology.

[14]  Franca Ronchese,et al.  The VITAL assay: a versatile fluorometric technique for assessing CTL- and NKT-mediated cytotoxicity against multiple targets in vitro and in vivo. , 2004, Journal of immunological methods.

[15]  K. Schroder,et al.  Interferon‐γ: an overview of signals, mechanisms and functions , 2004 .

[16]  J. Christensen,et al.  Deficient CD4+ T Cell Priming and Regression of CD8+ T Cell Functionality in Virus-Infected Mice Lacking a Normal B Cell Compartment 1 , 2003, The Journal of Immunology.

[17]  H. Pircher,et al.  A Critical Requirement of Interferon γ-mediated Angiostasis for Tumor Rejection by CD8+ T Cells , 2003 .

[18]  T. Tüting,et al.  Adenovirus-transduced dendritic cells stimulate cellular immunity to melanoma via a CD4+ T cell-dependent mechanism , 2001, Gene Therapy.

[19]  M. Cotten,et al.  MHC class II presentation of endogenously expressed antigens by transfected dendritic cells , 2001, Gene Therapy.

[20]  J. Krauss,et al.  T Cell-Mediated Tumor Rejection Displays Diverse Dependence Upon Perforin and IFN-γ Mechanisms That Cannot Be Predicted From In Vitro T Cell Characteristics1 , 2000, The Journal of Immunology.

[21]  P. Kourilsky,et al.  Recombinant viruses as a tool for therapeutic vaccination against human cancers. , 2000, Immunology letters.

[22]  M. Neuenhahn,et al.  Differential requirement of perforin and IFN‐γ in CD8 T cell‐mediated immune responses against B16.F10 melanoma cells expressing a viral antigen , 2000, European journal of immunology.

[23]  J. Christensen,et al.  Compromised virus control and augmented perforin-mediated immunopathology in IFN-gamma-deficient mice infected with lymphocytic choriomeningitis virus. , 1999, Journal of immunology.

[24]  B. Fox,et al.  Tumor regression after adoptive transfer of effector T cells is independent of perforin or Fas ligand (APO-1L/CD95L). , 1999, Journal of immunology.

[25]  H. Pircher,et al.  Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo. , 1998, Journal of immunology.

[26]  S. Sambhara,et al.  Enhanced antibody and cytokine responses to influenza viral antigens in perforin-deficient mice. , 1998, Cellular immunology.

[27]  R. Schreiber,et al.  Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice , 1998 .

[28]  T. Mak,et al.  Duration of TCR stimulation determines costimulatory requirement of T cells. , 1996, Immunity.

[29]  M. Nerenberg,et al.  Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model: Role of anti-self (virus) immune response , 1991, Cell.

[30]  R. Herberman,et al.  Lymphocyte-mediated cytotoxicity. , 1987, Pediatric annals.

[31]  P. Briand,et al.  The effect of estrone-progesterone treatment on cell proliferation kinetics of hormone-dependent GR mouse mammary tumors. , 1975, Cancer research.

[32]  T. Mak,et al.  TNF-alpha is critical for antitumor but not antiviral T cell immunity in mice. , 2007, The Journal of clinical investigation.

[33]  K. Schroder,et al.  Interferon-gamma: an overview of signals, mechanisms and functions. , 2004, Journal of leukocyte biology.

[34]  H. Pircher,et al.  A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells. , 2003, Cancer research.

[35]  L. Travassos,et al.  Endogenous accumulation of IFN-? in IFN-?-R -/- mice increases resistance to B16F10-Nex2 murine melanoma: a model for direct IFN-? anti-tumor cytotoxicity in vitro and in vivo , 2002 .

[36]  L. Travassos,et al.  Endogenous accumulation of IFN-gamma in IFN-gamma-R(-/-) mice increases resistance to B16F10-Nex2 murine melanoma: a model for direct IFN-gamma anti-tumor cytotoxicity in vitro and in vivo. , 2002, Cytokines, cellular & molecular therapy.

[37]  R. Dutton,et al.  Immunopotentiating role of IFN-gamma in early and late stages of type 1 CD8 effector cell-mediated tumor rejection. , 2001, Clinical immunology.

[38]  G. Beatty,et al.  Regulation of tumor growth by IFN-γ in cancer immunotherapy , 2001 .

[39]  J. Krauss,et al.  T Cell-Mediated Tumor Rejection Displays Diverse Dependence Upon Perforin and IFN- g Mechanisms That Cannot Be Predicted From In Vitro T Cell Characteristics , 2000 .

[40]  R. Schreiber,et al.  Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[41]  R. Zinkernagel,et al.  Molecular mechanisms of lymphocyte-mediated cytotoxicity and their role in immunological protection and pathogenesis in vivo. , 1996, Annual review of immunology.

[42]  C. Newgard,et al.  Use of recombinant adenovirus for metabolic engineering of mammalian cells. , 1994, Methods in cell biology.

[43]  H. zur Hausen.  Viruses in human cancers. , 1991, Science.